Me33,
Much safer? AMRN will do $175 million in revenues this year. Consistently growing scripts. The drug is very safe. There is 100% probability that AMRN has a >15%RRR in PE. There pipeline is getting other indications for Vascepa due to their 1st amendment win. Multiple billion dollar revenue co within next few years. VCEL has a great pipeline as well but won't reach revenue potential that AMRN will when Reduce-It shows that reducing inflammation is the key $ maker.
"VCEL is a much safer and with greater potential stock than AMRN. IMO chances of RI being successful is 50/50. If RI fails the stock will crush instantly and never recover. Very risky.
Not to mention that AMRN, a company with a single drug and no pipeline, already trades at $1bil+ market cap. "
News 
Market Data 
Discover 
